The European Medicine’s Agency (EMA) has said it is “firmly convinced” that the benefits of the AstraZeneca Covid-19 vaccine “outweigh the risks of the side effects”.
A number of countries including Ireland suspended the use of this particular Covid-19 vaccine amid concerns over blood clots.
Over the past few days, the EMA has been carrying out an investigation into the vaccine after reports of rare blood-clotting events, including some complicated by very low levels of platelets in the blood of younger adults, after vaccination.
A statement released by the EMA said it “currently remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects”.
The EMA’s safety committee (PRAC) is set to further review the information today and has called an extraordinary meeting tomorrow “to conclude on the information gathered and any further actions that may need to be taken”.